Verastem (VSTM) Q2 2026 Earnings Call Transcript
Verastem (VSTM) reported Q2 2026 net product revenue of $25.1M from the AVMAPKI FAKZYNJA CO-PACK launch and total revenue of $40.1M, including a $15M Secura Bio milestone. Non-GAAP adjusted net loss was $30.6M ($0.31/share). Cash and investments were $136.4M; pro forma cash $201.4M. VS-7375 Phase II trials advanced.
How this was made
The 30-second read
Why it matters
Key trading levers are (1) nondilutive financing and milestone cash that extends runway, (2) revenue growth tied to the CO-PACK commercial launch, and (3) early clinical response rates and trial initiation that affect probability-weighted timelines into Phase III planning.
Market read
Traders can update models for VSTM based on the disclosed cash runway extension, revenue/milestone inflows, and early clinical response rates that may shift near-term valuation and event-risk into October and Phase III planning.
What to watch
The article highlights multiple programs and cohorts, but does not provide full guidance ranges or detailed cost/operating leverage beyond the quarter, leaving execution risk underappreciated.
Background
Verastem Oncology held its Q2 2026 earnings call, covering commercial progress for its CO-PACK launch, VS-7375 clinical development, and balance-sheet financing.
Ticker impact
Verastem reported Q2 2026 results and guided pro forma cash to fund operations into 2H 2027, tied to CO-PACK launch and milestones.
Moderate upside bias on renewed confidence in cash runway and clinical momentum; volatility likely around October update and Phase III planning.
The article discloses multiple concrete datapoints: revenue, adjusted loss, $75M nondilutive royalty financing with $50M received at closing, $15M Secura Bio milestone, and specific response rates in RAMP 201/205, all of which can affect valuation and probability-weighted timelines.
Market effects
Reinforces the biotech funding narrative that nondilutive royalty structures can extend runway while advancing registration-directed trials.
Limited direct regional read-through; Japan-specific RAMP 201 response rates may support global sentiment for LGSOC programs.
Milestone triggers tied to worldwide net sales and FDA Fast Track designation can influence broader oncology investor risk appetite.
Counterpoint
Cash runway extension may still be insufficient if CO-PACK commercial uptake or milestone timing slips, and clinical endpoints are early-stage.
Key entities
- companyVerastem, Inc.
Subject of the earnings call transcript, reporting Q2 2026 financials, CO-PACK commercial launch progress, VS-7375 trial updates, and cash runway guidance.
- partnerSecura Bio
Partner whose $15M milestone is triggered by reaching $200M cumulative worldwide net sales of COPIKTRA.
- financing counterpartOberland Capital
Provided a $75M nondilutive royalty financing agreement, with $50M received at closing and additional funding tied to CO-PACK net sales.
- partnerErasca
Agreement to evaluate VS-7375 in combination with a pan-RAS molecular glue across KRAS G12D mutant solid tumor models.
- regulatorFDA
Fast Track designation referenced for non-small cell lung cancer and planned end-of-2026 meeting to review Phase III designs.
